Assessment of activity limitations and participation restrictions with persons with chronic fatigue syndrome: a systematic review.
Vergauwen, Kuni, Huijnen, Ivan P J, Kos, Daphne et al. · Disability and rehabilitation · 2015 · DOI
Quick Summary
This study looked at different questionnaires and tests that doctors use to measure how much ME/CFS affects a person's daily activities and ability to participate in life. Researchers reviewed 68 studies and found that most of these tools haven't been properly tested to make sure they accurately measure ME/CFS limitations. They recommend using a disease-specific tool called the CFS-APQ if doctors need to measure these limitations, although even this tool needs more research to be fully validated.
Why It Matters
Standardized, validated measurement tools are essential for clinicians to objectively assess the real-world impact of ME/CFS on patients' lives and for researchers to evaluate treatment effectiveness. This review identifies a significant gap in the field—most existing tools lack sufficient validation in ME/CFS populations—and provides evidence-based guidance for practitioners seeking reliable instruments.
Observed Findings
Only 8 of 68 identified articles formally evaluated psychometric properties of activity/participation measurement instruments in ME/CFS patients.
One disease-specific instrument (CFS-APQ) and 37 generic instruments were found in the literature.
The CFS-APQ demonstrated moderate content validity and moderate construct validity for ME/CFS populations.
Limited evidence exists for the psychometric properties and clinical usability of most reviewed instruments.
Most generic instruments lack validation data specific to ME/CFS populations.
Inferred Conclusions
Current measurement instruments assessing activity limitations and participation restrictions in ME/CFS lack sufficient psychometric evaluation.
The CFS-APQ is the only disease-specific instrument available and is recommended for clinical and research use until better alternatives are developed.
Significant future research is needed to validate both the CFS-APQ and other promising instruments in ME/CFS populations.
Standardized, validated measurement tools are critical gaps that limit precise assessment of functional impact in ME/CFS.
Remaining Questions
What are the complete psychometric properties of the CFS-APQ, including reliability, responsiveness to change, and minimal clinically important difference?
What This Study Does Not Prove
This systematic review does not prove that current measurement instruments are ineffective; rather, it demonstrates that their psychometric properties have not been adequately evaluated in ME/CFS cohorts. It does not establish superiority of the CFS-APQ over other tools, only that it has the most favorable evidence available. The review cannot determine whether instruments perform differently based on ME/CFS severity or disease subtype.